European equities traded in the US as American depositary receipts were trending lower late Wednesday morning, declining 0.49% to 1,307.19 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies (DBVT) and Genfit (GNFT), which rose 5.3% and 4.8% respectively. They were followed by pharmaceutical company Novo Nordisk (NVO) and biopharmaceutical company argenx (ARGX), which were up 2.2% and 1.9% respectively.
The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and semiconductor company Sequans Communications (SQNS), which fell 7.9% and 5.2% respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company Grifols (GRFS), which dropped 2.8% and 2.4% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Amarin (AMRN) and cruise line operator Carnival (CUK), which increased 2.7% and 0.6% respectively. They were followed by financial services company HSBC (HSBC) and mining company BHP Group (BHP), which were up 0.5% and 0.3% respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and TC Biopharm (TCBP), which shed 8.3% and 7.6% respectively. They were followed by biotech firm Trinity Biotech plc (TRIB) and biopharmaceutical company NuCana (NCNA), which lost 6.8% and 5.7% respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。